川芎—赤芍药对研究进展
|
摘要
川芎—赤芍是著名的活血化瘀药对,川芎活血行气、祛风止痛,赤芍清热凉血、散瘀止痛,二者均为活血要药,配伍后达到同类相须、相辅相成、相互促进等功用,能够发挥抗动脉粥样硬化,改善血液流变性,改善心肌缺血,保护内皮功能,保护脑组织及神经等作用。芎芍胶囊是川芎和赤芍有效组分配伍的典型应用,主要用于治疗心血管疾病。本文从功效及物质基础、药理研究、临床应用方面对川芎—赤芍药对的研究进行了系统的阐述,以期为川芎—赤芍药对的进一步研究与开发提供依据。
Rhizoma Chuanxiong-Radix Paeoniae Rubra is a famous herb pair for activating blood circulation and removing blood stasis. Rhizoma Chuanxiong invigorates qi and blood circulation,dispels wind and relieves pain. Radix Paeoniae Rubra removes pathogenic heat to cool blood,removes stasis to relieve pain. They are important herb pair of activating blood circulation with mutual promotion and mutual supplement in Chinese medicine,and play important roles in anti-atherosclerosis,improving blood rheology and myocardial ischemia,protecting endothelial function,brain tissue and nerve et al.Xiongshao capsules are the typical application of the compatibilites of effective components of Rhizoma Chuanxiong and Radix Paeoniae Rubra,which are mainly used to treat cardiovascular diseases in clinical practice. In this paper,efficacy, material basis,pharmacological research and clinical application of Rhizoma Chuanxiong-Radix Paeoniae Rubra herb pair were systematically described,so as to provide the evidence for the further research and development of Rhizoma Chuanxiong-Radix Paeoniae Rubra herb pair.
Rhizoma Chuanxiong-Radix Paeoniae Rubra is a famous herb pair for activating blood circulation and removing blood stasis. Rhizoma Chuanxiong invigorates qi and blood circulation,dispels wind and relieves pain. Radix Paeoniae Rubra removes pathogenic heat to cool blood,removes stasis to relieve pain. They are important herb pair of activating blood circulation with mutual promotion and mutual supplement in Chinese medicine,and play important roles in anti-atherosclerosis,improving blood rheology and myocardial ischemia,protecting endothelial function,brain tissue and nerve et al.Xiongshao capsules are the typical application of the compatibilites of effective components of Rhizoma Chuanxiong and Radix Paeoniae Rubra,which are mainly used to treat cardiovascular diseases in clinical practice. In this paper,efficacy, material basis,pharmacological research and clinical application of Rhizoma Chuanxiong-Radix Paeoniae Rubra herb pair were systematically described,so as to provide the evidence for the further research and development of Rhizoma Chuanxiong-Radix Paeoniae Rubra herb pair.
引文
[1] 蒋跃绒,谢元华,张京春,等.陈可冀治疗心血管疾病血瘀证用药规律数据挖掘[J].中医杂志,2015,56(5):376-380.
[2] 韩炜.川芎的化学成分与药理作用研究进展[J].中国现代中药,2017,19(9):1341-1349.
[3] 陆小华,马骁,王建,等.赤芍的化学成分和药理作用研究进展[J].中草药,2015,46(4):595-602.
[4] 袁蓉,王燕,丛伟红,等.芎芍胶囊治疗心血管病研究进展[J].中国中药杂志,2017,42 (4):640-643.
[5] 张伟杰,王鹏,杨明俊,等.川芎、赤芍多糖活性分析及其比较[J].中药材,2011,34(10):1569-1574.
[6] 李秀玲,肖红斌,徐青,等.中药川芎和赤芍配伍规律的方法研究[J].高等学校化学学报,2004,25(9):1632-1636.
[7] 李晓如,梁逸曾,杨辉,等.中药药对的化学成分研究川芎-赤芍挥发油的 GC/MS分析[J].高等学校化学学报,2006,27(3):443-448.
[8] 张壮,刘楠,陈可冀,等.川芎赤芍配伍比例对阿魏酸在麻醉犬体内药代动力学的影响[J].中国实验方剂学杂志,2005,11(3):28-31.
[9] 张壮,闫彦芳,陈可冀.川芎赤芍配伍比例对芍药苷药代动力学的影响[J].中国中药杂志,2000,25(11):688-690.
[10] 徐浩,文川,陈可冀,等.川芎、赤芍及其有效部位配伍对载脂蛋白E基因缺陷小鼠动脉粥样硬化斑块稳定性影响的研究[J].中国中西医结合杂志,2007,27(6):513-518.
[11] ZHANG Y H,ZHANG Y,LI J,et al.Protective effects of Xiongshao Capsule (芎芍胶囊) on anti-inflammatory function of high-density lipoprotein in an atherosclerosis rabbit model[J].Chin J Integr Med,2015,23(5):357-361.
[12] ZHANG L,JIANG Y R,GUO C Y,et al.Effects of active components of Red Paeonia and Rhizoma chuanxiong on angiogenesis in atherosclerosis plaque in rabbits[J].Chin J Integr Med,2009,15(5):359-364.
[13] 王景尚.赤芍川芎有效部位对波动性高血糖介导血管内皮损伤过程中血小板活化及PKCβ1表达的影响[J].中国中医科学院,2014:1-10.
[14] 姚旭,于文会.赤芍和川芎及其配伍对血淤模型大鼠血液流变学影响[J].动物医学进展,2013,34(6):120-122.
[15] 刘剑刚,徐凤芹,史大卓,等.川芎赤芍提取物不同配比的活血化瘀作用研究[J].中药新药与临床药理,2005,16(5):315-317.
[16] WANG Y,GUO G,YANG B R,et al.Synergistic effects of Chuanxiong-Chishao herb-pair on promoting angiogenesis at network pharmacological and pharmacodynamic levels[J].Chin J Integr Med,2017,23(9):654-662.
[17] 陈宁宇,严萍,林久茂,等.超声下观察芎芍胶囊对心肌梗死大鼠缺血心肌血管新生的作用[J].中西医结合心脑血管病杂志,2012,10(2):191-192.
[18] 梁日欣,黄璐琦,刘菊福,等.药对川芎和赤芍对高脂血症大鼠降脂、抗氧化及血管内皮功能的实验观察[J].中国实验方剂学杂志,2002,8(1):43-45.
[19] 顾俊菲,封亮,袁嘉瑞,等.赤芍总苷、川芎总酚酸组分组成结构对缺氧损伤人脐静脉内皮细胞的影响[J].中国中药杂志,2015,40(5):920-926.
[20] GU J,CHEN J,YANG N,et al.Combination of Ligusticum chuanxiong and Radix Paeoniae ameliorate focal cerebral ischemic in MCAO rats via endoplasmic reticulum stress-dependent apoptotic signaling pathway[J].J Ethnopharmacol,2016,187:313-324.
[21] 马进,甘雨,袁媛,等.川芎赤芍对脑缺血再灌注大鼠模型GFAP、VEGF及Notch1表达的影响[J].世界科学技术:中医药现代化,2016,18(5):821-825.
[22] 马进,甘雨,袁媛,等.川芎赤芍干预脑缺血再灌注大鼠血管新生的实验研究[J].世界中医药,2016,11(6):1060-1062.
[23] CHEN K J,SHI D Z,XU H,et al.XS0601 reducesthe incidence of the restenosis:a prospective study of 335 patients undergoing percutaneous coronary intervention in China[J].Chin J Chin Med,2006,119(1):6-13.
[24] SHANG Q H,XU H,LU X Y,et al.A multi-center randomized double-blind placebo-controlled trial of Xiongshao Capsule in preventing restenosis after percutaneous coronary intervention:a subgroup analysis of senile patients[J].Chin J Integr Med,2011,17(9):669-674.
[25] ZHENG G H,LIU J P,CHU J F,et al.Xiongshao for restenosis after percutaneous coronary intervention in patients with coronaryheart disease[J].Cochrane Database Syst Rev,2013,31(5):CD009581.
[26] 徐凤芹.芎芍胶囊防治动脉粥样硬化血管重构的临床与实验研究[D].山东:山东中医药大学,2003:1-20.
[27] 彭伟,史大卓,薛一涛,等.芎芍胶囊治疗冠心病心绞痛心血瘀阻证112例临床研究[J].中国中西医结合杂志,2011,31(2):191-194.
[28] 李康清,吴新富.芎芍胶囊治疗冠心病心绞痛的临床观察及血清超敏c反应蛋白的变化[J].数理医药学杂志,2015,28(11):1690-1691.
[29] 王学玲.芎芍胶囊对改善冠心病患者血管内皮功能的临床研究[J].中国医学工程.,2012,20(2):38-39.
[30] 唐于平,束晓云,李伟霞,等.药对研究(Ⅰ)——药对的形成与发展[J].中国中药杂志,2013,38(24):4185-4190.
[31] 李建波,张莉,张洁.药对配伍理论及相关研究概述[J].中医杂志,2013,54(15):1335-1340.
[2] 韩炜.川芎的化学成分与药理作用研究进展[J].中国现代中药,2017,19(9):1341-1349.
[3] 陆小华,马骁,王建,等.赤芍的化学成分和药理作用研究进展[J].中草药,2015,46(4):595-602.
[4] 袁蓉,王燕,丛伟红,等.芎芍胶囊治疗心血管病研究进展[J].中国中药杂志,2017,42 (4):640-643.
[5] 张伟杰,王鹏,杨明俊,等.川芎、赤芍多糖活性分析及其比较[J].中药材,2011,34(10):1569-1574.
[6] 李秀玲,肖红斌,徐青,等.中药川芎和赤芍配伍规律的方法研究[J].高等学校化学学报,2004,25(9):1632-1636.
[7] 李晓如,梁逸曾,杨辉,等.中药药对的化学成分研究川芎-赤芍挥发油的 GC/MS分析[J].高等学校化学学报,2006,27(3):443-448.
[8] 张壮,刘楠,陈可冀,等.川芎赤芍配伍比例对阿魏酸在麻醉犬体内药代动力学的影响[J].中国实验方剂学杂志,2005,11(3):28-31.
[9] 张壮,闫彦芳,陈可冀.川芎赤芍配伍比例对芍药苷药代动力学的影响[J].中国中药杂志,2000,25(11):688-690.
[10] 徐浩,文川,陈可冀,等.川芎、赤芍及其有效部位配伍对载脂蛋白E基因缺陷小鼠动脉粥样硬化斑块稳定性影响的研究[J].中国中西医结合杂志,2007,27(6):513-518.
[11] ZHANG Y H,ZHANG Y,LI J,et al.Protective effects of Xiongshao Capsule (芎芍胶囊) on anti-inflammatory function of high-density lipoprotein in an atherosclerosis rabbit model[J].Chin J Integr Med,2015,23(5):357-361.
[12] ZHANG L,JIANG Y R,GUO C Y,et al.Effects of active components of Red Paeonia and Rhizoma chuanxiong on angiogenesis in atherosclerosis plaque in rabbits[J].Chin J Integr Med,2009,15(5):359-364.
[13] 王景尚.赤芍川芎有效部位对波动性高血糖介导血管内皮损伤过程中血小板活化及PKCβ1表达的影响[J].中国中医科学院,2014:1-10.
[14] 姚旭,于文会.赤芍和川芎及其配伍对血淤模型大鼠血液流变学影响[J].动物医学进展,2013,34(6):120-122.
[15] 刘剑刚,徐凤芹,史大卓,等.川芎赤芍提取物不同配比的活血化瘀作用研究[J].中药新药与临床药理,2005,16(5):315-317.
[16] WANG Y,GUO G,YANG B R,et al.Synergistic effects of Chuanxiong-Chishao herb-pair on promoting angiogenesis at network pharmacological and pharmacodynamic levels[J].Chin J Integr Med,2017,23(9):654-662.
[17] 陈宁宇,严萍,林久茂,等.超声下观察芎芍胶囊对心肌梗死大鼠缺血心肌血管新生的作用[J].中西医结合心脑血管病杂志,2012,10(2):191-192.
[18] 梁日欣,黄璐琦,刘菊福,等.药对川芎和赤芍对高脂血症大鼠降脂、抗氧化及血管内皮功能的实验观察[J].中国实验方剂学杂志,2002,8(1):43-45.
[19] 顾俊菲,封亮,袁嘉瑞,等.赤芍总苷、川芎总酚酸组分组成结构对缺氧损伤人脐静脉内皮细胞的影响[J].中国中药杂志,2015,40(5):920-926.
[20] GU J,CHEN J,YANG N,et al.Combination of Ligusticum chuanxiong and Radix Paeoniae ameliorate focal cerebral ischemic in MCAO rats via endoplasmic reticulum stress-dependent apoptotic signaling pathway[J].J Ethnopharmacol,2016,187:313-324.
[21] 马进,甘雨,袁媛,等.川芎赤芍对脑缺血再灌注大鼠模型GFAP、VEGF及Notch1表达的影响[J].世界科学技术:中医药现代化,2016,18(5):821-825.
[22] 马进,甘雨,袁媛,等.川芎赤芍干预脑缺血再灌注大鼠血管新生的实验研究[J].世界中医药,2016,11(6):1060-1062.
[23] CHEN K J,SHI D Z,XU H,et al.XS0601 reducesthe incidence of the restenosis:a prospective study of 335 patients undergoing percutaneous coronary intervention in China[J].Chin J Chin Med,2006,119(1):6-13.
[24] SHANG Q H,XU H,LU X Y,et al.A multi-center randomized double-blind placebo-controlled trial of Xiongshao Capsule in preventing restenosis after percutaneous coronary intervention:a subgroup analysis of senile patients[J].Chin J Integr Med,2011,17(9):669-674.
[25] ZHENG G H,LIU J P,CHU J F,et al.Xiongshao for restenosis after percutaneous coronary intervention in patients with coronaryheart disease[J].Cochrane Database Syst Rev,2013,31(5):CD009581.
[26] 徐凤芹.芎芍胶囊防治动脉粥样硬化血管重构的临床与实验研究[D].山东:山东中医药大学,2003:1-20.
[27] 彭伟,史大卓,薛一涛,等.芎芍胶囊治疗冠心病心绞痛心血瘀阻证112例临床研究[J].中国中西医结合杂志,2011,31(2):191-194.
[28] 李康清,吴新富.芎芍胶囊治疗冠心病心绞痛的临床观察及血清超敏c反应蛋白的变化[J].数理医药学杂志,2015,28(11):1690-1691.
[29] 王学玲.芎芍胶囊对改善冠心病患者血管内皮功能的临床研究[J].中国医学工程.,2012,20(2):38-39.
[30] 唐于平,束晓云,李伟霞,等.药对研究(Ⅰ)——药对的形成与发展[J].中国中药杂志,2013,38(24):4185-4190.
[31] 李建波,张莉,张洁.药对配伍理论及相关研究概述[J].中医杂志,2013,54(15):1335-1340.